Exagen (NASDAQ:XGN) CEO John Aballi Sells 31,787 Shares of Stock

Exagen Inc. (NASDAQ:XGN) CEO John Aballi sold 31,787 shares of the company’s stock in a transaction on Thursday, October 16th. The stock was sold at an average price of $11.82, for a total value of $375,722.34. Following the sale, the chief executive officer owned 714,427 shares of the company’s stock, valued at $8,444,527.14. The trade was a 4.26% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Exagen Stock Up 1.6%

NASDAQ XGN opened at $11.72 on Tuesday. Exagen Inc. has a fifty-two week low of $2.38 and a fifty-two week high of $11.99. The stock has a market capitalization of $257.84 million, a PE ratio of -13.17 and a beta of 1.54. The company has a debt-to-equity ratio of 1.06, a current ratio of 4.95 and a quick ratio of 4.95. The business has a fifty day moving average price of $10.23 and a two-hundred day moving average price of $7.88.

Exagen (NASDAQ:XGN) last announced its quarterly earnings results on Tuesday, July 29th. The company reported ($0.18) EPS for the quarter, meeting analysts’ consensus estimates of ($0.18). Exagen had a negative return on equity of 130.38% and a negative net margin of 28.85%.The company had revenue of $17.20 million during the quarter, compared to analysts’ expectations of $16.25 million. Exagen has set its FY 2025 guidance at EPS. Equities analysts expect that Exagen Inc. will post -0.88 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on the company. Craig Hallum began coverage on Exagen in a research note on Wednesday, July 23rd. They issued a “buy” rating and a $12.00 price target for the company. B. Riley initiated coverage on Exagen in a report on Thursday, September 11th. They set a “buy” rating and a $15.00 price target for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Exagen in a report on Wednesday, October 8th. Cantor Fitzgerald restated an “overweight” rating and issued a $10.00 target price on shares of Exagen in a research note on Wednesday, July 30th. Finally, KeyCorp raised their price target on shares of Exagen from $12.00 to $15.00 and gave the company an “overweight” rating in a research report on Tuesday, October 14th. Eight research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $12.60.

Institutional Investors Weigh In On Exagen

A number of hedge funds have recently modified their holdings of XGN. Balyasny Asset Management L.P. bought a new stake in shares of Exagen in the 2nd quarter worth approximately $5,017,000. Russell Investments Group Ltd. purchased a new position in Exagen in the second quarter worth $1,540,000. FourWorld Capital Management LLC purchased a new position in Exagen in the second quarter worth $1,456,000. Manatuck Hill Partners LLC purchased a new stake in Exagen during the second quarter valued at about $1,222,000. Finally, Massar Capital Management LP boosted its position in Exagen by 715.7% during the second quarter. Massar Capital Management LP now owns 170,000 shares of the company’s stock valued at $1,187,000 after buying an additional 149,160 shares during the period. Institutional investors own 75.25% of the company’s stock.

About Exagen

Exagen Inc develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).